Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Pharmacological Treatment of Colorectal Cancer
share announcement

Pharmacological Treatment of Colorectal Cancer

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 15 September 2024 | Viewed by 3346

Special Issue Editor

Dr. Chih-ping Hsu

E-Mail Website
Guest Editor
Department of Biotechnology and Pharmaceutical Technology, Yuanpei University of Medical Technology, Hsinchu 300, Taiwan
Interests: cancer cell signaling; targeted therapy of colorectal cancer; anticancer natural products; cancer stem cells; cancer pathology

Special Issue Information

Dear Colleagues,

According to the statistical data of the World Health Organization, colorectal cancer (CRC) was the third most common cancer type and the second most common cause of cancer death worldwide in 2020, and it leads to almost 1 million deaths per year. The treatment strategies of CRC are still a very important medical issue for human health.1,2

The treatment for CRC is divided into two parts: local treatments and systemic treatments. The local treatments for CRC, including surgery,  ablation, embolization, and radiation therapy, are useful for earlier-stage cancers without deep invasion or metastasis. However, more than 85 percent of colorectal cancers are found to be advanced, deeply invaded or even metastasized. Systemic treatments using pharmacological strategies including chemotherapy, targeted therapy, and immunotherapy are used in patients with advanced and metastatic colorectal cancer.3 Even though recent advances have improved colorectal cancer survival rates, the effectiveness of treatment and the quality of life of patients still requires more improvement.

In this Special Issue, we invite experts and research teams in this field to propose advanced pharmacological treatment strategies to improve the efficacy of colorectal cancer treatment and improve the quality of life of patients. We welcome original or review articles on discussing novel medications of CRC in targeted therapy, immunotherapy, and anti-angiogenesis agents and their molecular mechanisms, accompanying biomarkers. or pharmacogenomics.  Our sincere hope is that through this Special Issue, there will be a breakthrough in the treatment of colorectal cancer.

  1. https://www.iarc.who.int/cancer-type/colorectal-cancer/
  2. https://www.wcrf.org/cancer-trends/colorectal-cancer-statistics/
  3. https://www.cancer.org/cancer/colon-rectal-cancer/treating.html

Dr. Chih-ping Hsu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • chemotherapy
  • targeted therapy
  • immunotherapy
  • quality of life
  • molecular marker
  • cancer prevention

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2662 KiB  
Article
Sulfarotene Inhibits Colorectal Cancer via Mitigating Natural-Killer-Cell-Induced Stemness
by Keshu Hu, Yu Dong, Jiayu Zhang, Mengling Liu, Xun Sun, Xin Cao, Pengfei Zhang and Tianshu Liu
Pharmaceuticals 2024, 17(3), 387; https://doi.org/10.3390/ph17030387 - 18 Mar 2024
Viewed by 651
Abstract
Tumor cell stemness stands out as a pivotal factor driving tumor recurrence or metastasis and significantly contributes to the mortality of patients with colorectal cancer (CRC). Recent research has unveiled a link between immune-active cells and the induction of tumor cell stemness, ultimately [...] Read more.
Tumor cell stemness stands out as a pivotal factor driving tumor recurrence or metastasis and significantly contributes to the mortality of patients with colorectal cancer (CRC). Recent research has unveiled a link between immune-active cells and the induction of tumor cell stemness, ultimately leading to heightened resistance to treatment. In this study, stemness in CRC cell lines was assessed after co-culture with natural killer (NK) cells, both with and without sulfarotene administration. Furthermore, a CRC xenograft model was utilized to scrutinize the in vivo efficacy of sulfarotene in overcoming stemness induced by NK cell activation. As a result, CRC cells exhibited significant stemness after NK cell co-culture, as evidenced by the upregulation of several stemness markers associated with cancer stem cells. Moreover, these cells demonstrated remarkable resistance to commonly used chemotherapy agents for CRC, such as oxaliplatin and irinotecan. Importantly, sulfarotene effectively reversed the altered stemness of CRC cells in both in vitro and in vivo assays. In conclusion, sulfarotene emerges as a promising therapeutic strategy for overcoming colorectal cancer resistance to NK cells by effectively inhibiting stemness remodeling. This study underscores the potential of sulfarotene in augmenting NK-cell-mediated immune surveillance, proposing a novel immunotherapeutic approach against colorectal cancer. Full article
(This article belongs to the Special Issue Pharmacological Treatment of Colorectal Cancer)
►▼ Show Figures

Figure 1

13 pages, 4635 KiB  
Article
Tocilizumab Exerts Anti-Tumor Effects on Colorectal Carcinoma Cell Xenografts Corresponding to Expression Levels of Interleukin-6 Receptor
by Yuan-Chiang Chung, Szu-Jung Chen, Chiu-Chen Huang, Wei-Chun Liu, Ming-Tsung Lai, Ting-Yu Kao, Wei-Shun Yang, Chien-Hui Yang, Chih-Ping Hsu and Jia-Feng Chang
Pharmaceuticals 2024, 17(1), 127; https://doi.org/10.3390/ph17010127 - 18 Jan 2024
Viewed by 939
Abstract
The use of tocilizumab against the interleukin-6 receptor (IL-6R) has been demonstrated as inhibiting the progression of diverse cancers in vitro and in vivo. Nonetheless, evidence regarding the anti-tumor effects of tocilizumab on human colorectal carcinoma (CRC) corresponding to IL-6R expression levels remains [...] Read more.
The use of tocilizumab against the interleukin-6 receptor (IL-6R) has been demonstrated as inhibiting the progression of diverse cancers in vitro and in vivo. Nonetheless, evidence regarding the anti-tumor effects of tocilizumab on human colorectal carcinoma (CRC) corresponding to IL-6R expression levels remains scarce. To investigate the influence of IL-6R expression, SW480 and HT-29 cells inoculated subcutaneously into NU/NU mice were used as human CRC xenograft models with anti-IL-6R antibody (tocilizumab) therapy. The IL-6R expression levels, histology of CRC growth/invasiveness, and tumor growth-related signaling pathway were estimated by H&E and immunohistochemical staining. SW480 tumor cells with higher IL-6R expression levels showed better responsiveness in tocilizumab therapy than in the treated HT-29 group. Likewise, therapeutic effects of tocilizumab on the proliferative ability with mitotic index and Ki-67 expressions, invasiveness with MMP-9 proteinase expressions, and ERK 1/2 and STAT3 signaling transduction in the SW480 treatment group were superior to the HT-29 treatment group. In light of our results, IL-6R is the key indicator for the efficacy of tocilizumab treatment in CRC xenografts. From the perspective of precision medicine, tumor response to anti-IL-6R antibody therapy could be predicted on the basis of IL-6R expression levels. In this manner, tocilizumab may serve as a targeted and promising anti-CRC therapy. Full article
(This article belongs to the Special Issue Pharmacological Treatment of Colorectal Cancer)
►▼ Show Figures

Figure 1

15 pages, 3313 KiB  
Article
Immunohistochemical Expression of Glutathione Peroxidase 1 (Gpx-1) as an Independent Prognostic Factor in Colon Adenocarcinoma Patients
by Marlena Brzozowa-Zasada, Adam Piecuch, Karolina Bajdak-Rusinek, Kamil Janelt, Marek Michalski, Olesya Klymenko and Natalia Matysiak
Pharmaceuticals 2023, 16(5), 740; https://doi.org/10.3390/ph16050740 - 12 May 2023
Cited by 3 | Viewed by 1254
Abstract
Several studies revealed that expression levels of glutathione peroxidase 1 (Gpx-1) can be associated with cancer development, mainly through its role in hydroperoxide scavenging by regulating intracellular reactive oxygen species (ROS) levels. Therefore, our aim was to investigate the expression of Gpx-1 protein [...] Read more.
Several studies revealed that expression levels of glutathione peroxidase 1 (Gpx-1) can be associated with cancer development, mainly through its role in hydroperoxide scavenging by regulating intracellular reactive oxygen species (ROS) levels. Therefore, our aim was to investigate the expression of Gpx-1 protein in a population of Polish patients with colon adenocarcinoma in the absence of any therapy prior to radical surgery. The study was carried out using colon tissue from patients with adenocarcinoma of the colon confirmed by histopathological examination. Gpx-1 antibody was used to determine the immunohistochemical expression of Gpx-1. The Chi2test or Chi2Yatesa test were used to analyse the associations between the immunohistochemical expression of Gpx-1 and clinical parameters. The relationship between Gpx-1 expression, and 5-year patient survival was examined using Kaplan–Meier analysis and the log-rank test. Intracellular localisation of Gpx-1 was detected by the use of transmission electron microscopy (TEM). Western blot analysis was used for the evaluation of Gpx-1 protein expression levels in cancer cell lines in vitro. Immunohistochemical study revealed that the high expression of Gpx-1 was associated with the tumour’s histological grade, proliferating cell nuclear antigen (PCNA) immunohistochemical expression, depth of invasion, and angioinvasion (all p < 0.001) (4). The high immunohistochemical expression of Gpx-1 is correlated with poor prognosis of colon adenocarcinoma patients. Full article
(This article belongs to the Special Issue Pharmacological Treatment of Colorectal Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop